2025.10. 11 本文字数：2272，阅读时长大约4分钟 为继续培育未来产业，上海再发新政进行系统性布局。 10月11日，上海市政府新闻办举行市政府新闻发布会介绍了《关于加快推动前沿技术创新与未来产业培育的若干措 施》（下称"措施"），措施提出力争到2027年，突破一批前沿颠覆性技术，体系化布局建设一批未来产业集聚区，培 育20家左右未来产业生态主导型企业。到2030年，培育壮大一批未来产业，推动形成若干战略性新兴产业，成为具有 世界影响力的未来产业引领地。 作者 | 第一财经 金叶子 为何选定这些重点领域？ 在聚焦重点发展领域，提出围绕未来制造、未来信息、未来材料、未来能源、未来空间、未来健康六大方向，合理规 划、分层推进、精准培育。发展壮大细胞与基因治疗、脑机接口、生物制造、具身智能等领域，重点支持降低成本、 提高可及性、构建产业生态；加快培育第四代半导体、硅基光电子、第六代移动通信、类脑智能等领域，重点支持优 化产品设计、拓展应用场景、验证市场价值；加速布局量子科技、可控核聚变、再生医学等前沿领域，重点支持技术 难题攻关、技术路线收敛、产品可行性验证。 谈到为何选定这些方向，上海市科委副主任屈炜回 ...

新华财经上海10月11日电上海市人民政府办公厅印发《关于加快推动前沿技术创新与未来产业培育的若 干措施》。其中提到，聚焦重点发展领域，围绕未来制造、未来信息、未来材料、未来能源、未来空间 和未来健康等方向，结合产业基础和资源禀赋，合理规划、精准培育未来产业。发展壮大细胞与基因治 疗、脑机接口、生物制造、具身智能等领域，重点支持降低成本、提高可及性、构建产业生态，加速产 品工程化、产业化。加快培育第四代半导体、硅基光电子、第六代移动通信、类脑智能等领域，重点支 持优化产品设计、拓展应用场景、验证市场价值，加快原型样机或样品研究。加速布局量子科技、可控 核聚变、再生医学等领域，重点支持技术难题攻关、技术路线收敛，开展产品研发或技术方案可行性验 证。 在加强统筹协调方面，措施还提出，上海市科委会同市发展改革委、市经济信息化委、市财政局、市教 委、市国资委、市人才局、市规划资源局、上海国投公司等部门、单位按照职能分工，合力推进未来产 业培育。探索建立健全沙盒监管制度，加快鼓励创新、弹性包容的未来产业监管体系改革创新。建立健 全未来产业发展和战略性新兴产业接力培育推进机制。 详见全文：上海市人民政府办公厅印发《关于加快 ...

Group 1 - The core viewpoint of the event emphasizes the significant market growth potential of new therapies such as cell and gene therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), alongside the rapid development of artificial intelligence providing more possibilities for disease treatment [1] - The Chinese innovative drug industry has been accelerating its international expansion, with a notable increase in the accessibility of innovative biopharmaceuticals over the past decade [1] - The establishment of a standardized clinical-grade stem cell resource bank is identified as a core support for the sustainable development of the industry, necessitating simultaneous advancements in technological innovation and ethical regulations [1] Group 2 - The roundtable discussion highlighted the shift in human health perspectives from "fighting diseases" to "controlling life quality," driven by breakthroughs in emerging biotechnologies [2] - The event aims to bridge the gap between academia and industry, fostering cross-disciplinary exchanges to explore new paradigms and pathways for technological innovation [2] - Future discussions will focus on cutting-edge technologies such as artificial intelligence, photonics, and synthetic biology, promoting the integration of future technologies with future industries [2]

Investment Rating - The report maintains an "Outperform" rating for Genscript Biotech [2][4][6] Core Insights - The deconsolidation of Legend Biotech has led to a significant profit improvement for Genscript, with a profit from discontinued operations of approximately $3 billion, compared to a loss of about $518 million in the same period last year [7][17] - The company expects a positive trend for its continuing business segments in 2025, with projected revenues of $938 million, representing a year-on-year growth of 58% [2][8] - The total equity valuation of Genscript is estimated at $6.296 billion, translating to a target price of HK$22.78 per share [6][17] Summary by Segment Life Sciences Segment - Expected revenue for 2025 is $523 million, with a year-on-year growth rate of 15% and an adjusted operating profit of $104 million, also growing by 15% [13][14] - The segment's revenue in 2024 was approximately $454.9 million, up by 10.2% year-on-year, with an adjusted gross profit of about $237.7 million [14][17] Biologics Development Services Segment - Projected Fee-for-Service revenue for 2025 is $113 million, up by 19% year-on-year [14][17] - The segment's revenue in 2024 was about $95 million, down by 13.2% year-on-year, but showed signs of recovery in the second half of 2024 [14][17] Industrial Synthetic Biology Products Segment - Expected revenue for 2025 is $67 million, with a year-on-year growth rate of 25% [15][17] - The segment's revenue in 2024 was approximately $53.7 million, up by 24.6% year-on-year [14][17] Legend Biotech - Following the deconsolidation, the market capitalization of Legend Biotech was approximately $6.8 billion, with Genscript holding a 47.51% stake valued at about $3.231 billion [16][17]